AbbVie Skyrizi 360mg/2.4ml Solution for Injection

Skyrizi is an innovative interleukin-23 (IL-23) antagonist engineered to help manage chronic autoimmune conditions. It provides a highly targeted therapeutic approach for adults navigating moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This precise formulation is designed to support consistent care and improved quality of life. Administered through injection, this treatment is intended for use under professional medical guidance. Always consult your healthcare provider to determine if this therapy aligns with your specific health needs.

Active Ingredient: Risankizumab
Concentration: 360mg/2.4ml
Dosage Form: Solution for Injection
Indications: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis
Manufacturer: AbbVie
Therapeutic Class: Immunomodulatory Medicines